Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Axalimogene filolisbac: Phase I/II started

    Advaxis Inc. (NASDAQ:ADXS), Princeton, N.J. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Product: Axalimogene filolisbac (ADXS11-001, ADXS-HPV) (formerly Lovaxin C) Business: Cancer Molecular target: E7 …

    Published on 10/12/2015
  • BioChaperone Lispro: Phase Ib started

    Adocia S.A. (Euronext:ADOC; OTCQX:ADOCY), Lyon, France Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: BioChaperone Lispro Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: …

    Published on 10/12/2015
  • CMX-2043: Completed Phase IIa enrollment

    Ischemix Inc., Maynard, Mass. Product: CMX-2043 Business: Cardiovascular Molecular target: Protein kinase B (AKT) (AKT1) (PKB) (PKBA) Description: Small molecule that modulates the protein kinase B (AKT; AKT1; PKB; PKBA…

    Published on 10/12/2015
  • Durvalumab: Phase I/II started

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Durvalumab (MEDI4736) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Description: Human IgG1 mAb targeting PD-L1 …

    Published on 10/12/2015
  • Eltoprazine: Phase IIb halted

    Amarantus BioScience Holdings Inc. (OTCQX:AMBS), San Francisco, Calif. PsychoGenics Inc., Tarrytown, N.Y. Product: Eltoprazine Business: Neurology Molecular target: Serotonin (5-HT1A) receptor; Serotonin (5-HT1B) …

    Published on 10/12/2015
  • EnGeneIC Delivery Vehicle: Phase I started

    EnGeneIC Ltd., Lane Cove West, Australia Product: EnGeneIC Delivery Vehicle (EDV) Business: Cancer Molecular target: Epidermal growth factor receptor (EGFR) Description: Anucleate bacterially derived minicell coated …

    Published on 10/12/2015
  • EV06: Phase I/II started

    Encore Vision Inc., Fort Worth, Texas Product: EV06 Business: Ophthalmic Molecular target: NA Description: 1.5% lipoic acid choline ester, which breaks down into lipoic acid and choline Indication: Treat presbyopia …

    Published on 10/12/2015
  • Gerilimzumab: Phase I started

    arGEN-X N.V. (Euronext:ARGX), Breda, the Netherlands RuiYi Inc., La Jolla, Calif. Product: Gerilimzumab Business: Autoimmune Molecular target: Interleukin-6 (IL-6) Description: mAb against IL-6 Indication: Treat …

    Published on 10/12/2015
  • HPBCD: Phase IIb/III started

    Vtesse Inc., Gaithersburg, Md. Product: HPBCD (VTS-270) 2-hydroxypropyl-b-cyclodextrin Business: Endocrine/Metabolic Molecular target: NA Description: 2-hydroxypropyl-b-cyclodextrin targeting cholesterol and …

    Published on 10/12/2015
  • IFNalpha-Kinoid: Phase IIb started

    Neovacs S.A. (Euronext:ALNEV), Paris, France Product: IFNalpha-Kinoid (IFN-K) Business: Autoimmune Molecular target: Interferon (IFN) alpha Description: Immunotherapy against interferon (IFN) alpha Indication: Treat …

    Published on 10/12/2015
  • JNJ-56022473: Phase II started

    CSL Ltd. (ASX:CSL), Melbourne, Australia Xencor Inc. (NASDAQ:XNCR), Monrovia, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: JNJ-56022473 (formerly CSL362) Business: Cancer Molecular target: …

    Published on 10/12/2015
  • Lasmiditan: Phase III started

    CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD), Durham, N.C. Product: Lasmiditan (COL-144) Business: Neurology Molecular target: Serotonin (5-HT1F) receptor Description: Selective agonist of serotonin (5-HT1F) receptor …

    Published on 10/12/2015
  • LIPO-202: Phase II started

    Neothetics Inc. (NASDAQ:NEOT), San Diego, Calif. Product: LIPO-202 Business: Other Molecular target: Adrenergic receptor beta 2 (ADRB2) Description: Subcutaneous formulation of salmeterol xinafoate, a long-acting …

    Published on 10/12/2015
  • Liprotamase: Phase III started

    Anthera Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Liprotamase (Sollpura) (LY3031642) Business: Gastrointestinal Molecular target: Not available …

    Published on 10/12/2015
  • Livatag doxorubicin: Phase III ongoing

    Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO), Paris, France Product: Livatag doxorubicin (Livatag doxorubicin Transdrug) (BA-003) Business: Cancer Molecular target: DNA Description: Nanoparticle formulation of doxorubicin …

    Published on 10/12/2015
  • M923: Pivotal trial started

    Baxalta Inc. (NYSE:BXLT), Deerfield, Ill. Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), Cambridge, Mass. Product: M923, BAX 923 Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha Description: …

    Published on 10/12/2015
  • MGN1703: Completed Phase I enrollment

    Mologen AG (Xetra:MGN), Berlin, Germany Product: MGN1703 Business: Infectious Molecular target: Toll-like receptor 9 (TLR9) Description: Toll-like receptor 9 (TLR9) agonist based on double Stem Loop Immunomodulator (…

    Published on 10/12/2015
  • PB01: Phase I started

    Paranta Biosciences Ltd., Richmond, Australia Product: PB01 Business: Pulmonary Molecular target: NA Description: Recombinant human follistatin Indication: Treat cystic fibrosis (CF) Endpoint: Safety, pharmacokinetics …

    Published on 10/12/2015
  • PTVG-AR: Phase I started

    Madison Vaccines Inc., Madison, Wis. Product: PTVG-AR (MVI-118) Business: Cancer Molecular target: Androgen receptor Description: Plasmid DNA vaccine carrying the ligand binding domain of the human androgen receptor …

    Published on 10/12/2015
  • REP 2139-Mg: Phase IIb started

    Replicor Inc., Montreal, Quebec Product: REP 2139-Mg Business: Infectious Molecular target: NA Description: Magnesium chelate complex of a nucleic acid polymer (NAP) Indication: Treat HBeAg-negative chronic HBV …

    Published on 10/12/2015
  • REP 2165-Mg: Phase IIb started

    Replicor Inc., Montreal, Quebec Product: REP 2165-Mg Business: Infectious Molecular target: NA Description: Magnesium chelate complex of a nucleic acid polymer (NAP) Indication: Treat HBeAg-negative chronic HBV …

    Published on 10/12/2015
  • Reparixin: Phase II started

    Dompe Farmaceutici S.p.A., Milan, Italy Product: Reparixin (formerly repertaxin) Business: Cancer Molecular target: CXC chemokine receptor 1 (CXCR1); CXC chemokine receptor 2 (CXCR2) (IL8RB) Description: CXC chemokine …

    Published on 10/12/2015
  • RVT-101: Phase III started

    Axovant Sciences Ltd. (NYSE:AXON), Hamilton, Bermuda Product: RVT-101 (formerly SB742457) Business: Neurology Molecular target: Serotonin (5-HT6) receptor Description: Serotonin (5-HT6) receptor antagonist Indication: …

    Published on 10/12/2015
  • RXDX-107: Phase I/Ib started

    Ignyta Inc. (NASDAQ:RXDX), San Diego, Calif. Product: RXDX-107 (formerly CEP-40125) Business: Cancer Molecular target: NA Description: Alkyl ester of bendamustine encapsulated in human serum albumin Indication: Treat …

    Published on 10/12/2015
  • SB623: Phase II started

    SanBio Co. Ltd. (Tokyo:4592), Tokyo, Japan Product: SB623 Business: Inflammation Molecular target: NA Description: Allogeneic cells derived from genetically engineered bone marrow stromal cells obtained from healthy …

    Published on 10/12/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993